NEW YORK, Jan 10 – Qiagen Genomics said Wednesday that it has entered into three new licensing agreements involving its Masscode technology for high-throughput SNP genotyping.
The agreements, announced separately, involve Agilent Technologies, Japan’s Daiichi Pharmaceutical subsidiary of Daiichi Pure Chemicals (DPC), and the University of Washington School of Pharmacy.
Under the terms of Qiagen’s exclusive value-added reseller deal with Agilent, both companies agreed to actively promote each other’s technologies in combination. Agilent’s single-quadrupole liquid chromatography/mass spectrometry technology will be used with Qiagen’s Masscode technology to provide SNP genotyping systems that will be marketed by Quiagen.
A second phase of the agreement covers the companies’ joint development of new Masscode tag chemistry and mass spectrometry instrumentation for SNP discovery, proteomics , and other applications.
Under the terms of the agreement with DPC, Qiagen will sell a Masscode system to DPC and will also grant a non-exclusive license related technology that will enable DPC to provide SNP genotyping services to clients in Japan.
The agreement requires that DPC purchase its SNP genotyping chemistry and instrumentation from Qiagen for a five-year period. Qiagen will provide DPC with training and support during the first year of the agreement.
The terms of the agreement with the UW School of Pharmacy cover the school’s purchase of limited, non-exclusive rights to use Masscode for certain specifically defined projects. As part of the agreement, Qiagen obtains the exclusive right to negotiate with UW for exclusive worldwide licenses on any new invention, development, biological material or discovery that results from UW's use of the system.
Financial terms of the three agreements were not disclosed.